AU2005275023B2 - Compositions and methods for treatment of colitis - Google Patents

Compositions and methods for treatment of colitis Download PDF

Info

Publication number
AU2005275023B2
AU2005275023B2 AU2005275023A AU2005275023A AU2005275023B2 AU 2005275023 B2 AU2005275023 B2 AU 2005275023B2 AU 2005275023 A AU2005275023 A AU 2005275023A AU 2005275023 A AU2005275023 A AU 2005275023A AU 2005275023 B2 AU2005275023 B2 AU 2005275023B2
Authority
AU
Australia
Prior art keywords
group
alkyl
groups
treatment
dss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005275023A
Other languages
English (en)
Other versions
AU2005275023A1 (en
Inventor
Uruguaysito Benavides-Peralta
Nilesh D. Dagia
Douglas J. Goetz
Marianna Gonzalez-Murguiondo
Norikazu Harii
Leonard D. Kohn
Christopher J. Lewis
Giorgio Napolitano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio University
Original Assignee
Ohio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio University filed Critical Ohio University
Publication of AU2005275023A1 publication Critical patent/AU2005275023A1/en
Application granted granted Critical
Publication of AU2005275023B2 publication Critical patent/AU2005275023B2/en
Assigned to OHIO UNIVERSITY reassignment OHIO UNIVERSITY Request for Assignment Assignors: INTERTHYR CORPORATION
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
AU2005275023A 2004-03-16 2005-07-14 Compositions and methods for treatment of colitis Ceased AU2005275023B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2004317993 2004-03-16
US10/912,948 US7928132B2 (en) 2004-08-06 2004-08-06 Methods for the amelioration of episodes of acute or chronic ulcerative colitis
US10/912,948 2004-08-06
PCT/US2005/025067 WO2006019962A1 (en) 2004-08-06 2005-07-14 Compositions and methods for treatment of colitis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2004317993A Division AU2004317993A1 (en) 2004-03-16 2004-03-16 Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion

Publications (2)

Publication Number Publication Date
AU2005275023A1 AU2005275023A1 (en) 2006-02-23
AU2005275023B2 true AU2005275023B2 (en) 2012-03-01

Family

ID=35355847

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005275023A Ceased AU2005275023B2 (en) 2004-03-16 2005-07-14 Compositions and methods for treatment of colitis

Country Status (6)

Country Link
US (1) US7928132B2 (enExample)
EP (1) EP1773329A1 (enExample)
JP (1) JP5039550B2 (enExample)
AU (1) AU2005275023B2 (enExample)
CA (1) CA2575777C (enExample)
WO (1) WO2006019962A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9326972B2 (en) 2004-03-16 2016-05-03 Ohio University Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US9750723B2 (en) 2013-10-31 2017-09-05 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
US10392381B2 (en) 2014-07-18 2019-08-27 Ohio University Prevention and treatment of non-alcoholic fatty liver disease

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094056A1 (en) * 2003-09-15 2006-05-04 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose treat, and evaluate inflammatory and autoimmune diseases
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
FR2917087B1 (fr) 2007-06-05 2012-09-21 Galderma Res & Dev Nouveaux 4-phenyl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique.
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
JP5562939B2 (ja) 2008-04-09 2014-07-30 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル アクチン細胞骨格再編成及び細胞間ギャップ形成調節の方法
MX2011010616A (es) * 2009-04-09 2012-03-14 Univ North Carolina Metodos para tratar edema relacionado a isquemia-reperfusion.
WO2010127367A2 (en) * 2009-05-01 2010-11-04 Alfagene Bioscience, Inc. Human gastrointestinal stem cell-derived primary intestinal epithelial cell system and methods of use thereof
US9422262B2 (en) * 2010-09-24 2016-08-23 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
US10668092B2 (en) 2010-09-24 2020-06-02 The John Hopkins University Compositions and methods for treatment of inflammatory disorders
KR101213070B1 (ko) * 2010-11-09 2012-12-18 부산대학교 산학협력단 포스포리파아제 ｄ１억제제를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 조성물
WO2013134822A1 (en) 2012-03-13 2013-09-19 James Cook University Method for treating inflammation
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
US20140271666A1 (en) * 2013-03-14 2014-09-18 Immune Pharmaceuticals Ltd. Use of anti-eotaxin antibodies for treating inflammatory bowel disease
HRP20211629T1 (hr) 2013-09-13 2022-02-04 National University Corporation Chiba University Primjena r-ketamina i njegove soli kao lijekova
JP2016532456A (ja) 2013-09-18 2016-10-20 ジェームス・クック・ユニバーシティー 改変型抗炎症性タンパク質及び使用方法
CN105486869A (zh) * 2014-10-08 2016-04-13 江苏维赛科技生物发展有限公司 一种检测动物源食品中甲巯咪唑残留的酶联免疫试剂盒及其应用
KR101647918B1 (ko) * 2015-03-09 2016-08-11 성균관대학교산학협력단 포스포리파제 d2 억제제를 유효성분으로 포함하는 박테리아 감염 질환 예방 또는 치료용 조성물
CN118453559A (zh) * 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
EP4081201A4 (en) * 2019-12-24 2024-01-10 Aardvark Therapeutics Inc. Pharmaceutical composition for treatment or prevention of multiple inflammatory disorders
CN113730444A (zh) * 2021-07-27 2021-12-03 自然资源部第一海洋研究所 一种海带中可溶性膳食纤维在制备用于改善溃疡性结肠炎的药物和功能性食品中的应用
CN114288388B (zh) * 2022-01-25 2023-11-03 华中科技大学同济医学院附属协和医院 网膜素在制备炎症性肠病治疗药物中的应用
CN114903883A (zh) * 2022-05-19 2022-08-16 南华大学附属第一医院 甜菜碱在制备治疗溃疡性结肠炎的药物中的用途
CN116473966B (zh) * 2023-03-29 2025-06-13 广州医科大学 Sb-222200在抑制nlrp3炎症小体活化中的应用
CN119174731B (zh) * 2024-11-15 2025-03-14 温州医科大学附属口腔医院 一种pmc纳米酶及其制备方法
CN120899702A (zh) * 2025-08-06 2025-11-07 大连医科大学附属第一医院 黄素单加氧酶3抑制剂在制备预防和/或治疗急性胰腺炎药物中的应用
CN121489961A (zh) * 2026-01-14 2026-02-10 浙江工商大学 维生素D3在制备缓解MXene致慢性肠炎和/或肠-肝轴损伤的产品中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025756A2 (de) * 1998-11-02 2000-05-11 Dr. Falk Pharma Gmbh Arzneimittel zur topischen behandlung entzündlicher darmerkrankungen
US6365616B1 (en) * 1998-08-31 2002-04-02 Sentron Medical, Inc. Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases
WO2004017962A2 (en) * 2002-08-26 2004-03-04 S.L.A. Pharma Ag Tropical formulation comprising at least 5% of metronidazole in white petrolatum and its use in the anal and rectal region
AU2004317993A1 (en) * 2004-03-16 2005-10-13 Interthyr Corporation Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4734421A (en) * 1986-10-29 1988-03-29 Merck & Co., Inc. Anti-inflammatory substituted 2-benzyl-mercapto-imidazole and pyrimidine derivatives compositions and method of use therefor
US5480583A (en) 1991-12-02 1996-01-02 Intevep, S.A. Emulsion of viscous hydrocarbon in aqueous buffer solution and method for preparing same
US20050209295A1 (en) * 2004-03-16 2005-09-22 Kohn Leonard D Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365616B1 (en) * 1998-08-31 2002-04-02 Sentron Medical, Inc. Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases
WO2000025756A2 (de) * 1998-11-02 2000-05-11 Dr. Falk Pharma Gmbh Arzneimittel zur topischen behandlung entzündlicher darmerkrankungen
WO2004017962A2 (en) * 2002-08-26 2004-03-04 S.L.A. Pharma Ag Tropical formulation comprising at least 5% of metronidazole in white petrolatum and its use in the anal and rectal region
AU2004317993A1 (en) * 2004-03-16 2005-10-13 Interthyr Corporation Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Al Moutaery et al. Experimental and Toxicologic Pathology (2003) vol. 55, no. 4 pages 277-285 *
Dagia Nilesh et al. J. Immunology (2004) vol. 173, no. 3 pages 2041-2049* *
Isman et al. J.Endocrinology (2003) vol. 177, no. 3 pages 471-476 *
Oren et al. Alimentary Pharmacology and Therapeutics (1997) vol. 11, no. 2, pages 341-345 *
Singer Dinah et al. J. Immunology (1994) vol. 153, no. 2, pages 873-880 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9326972B2 (en) 2004-03-16 2016-05-03 Ohio University Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US9750723B2 (en) 2013-10-31 2017-09-05 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
US10392381B2 (en) 2014-07-18 2019-08-27 Ohio University Prevention and treatment of non-alcoholic fatty liver disease

Also Published As

Publication number Publication date
WO2006019962B1 (en) 2006-04-20
CA2575777C (en) 2011-01-11
JP5039550B2 (ja) 2012-10-03
EP1773329A1 (en) 2007-04-18
JP2008509137A (ja) 2008-03-27
CA2575777A1 (en) 2006-02-23
WO2006019962A1 (en) 2006-02-23
AU2005275023A1 (en) 2006-02-23
US7928132B2 (en) 2011-04-19
US20060058365A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
CA2575777C (en) Compositions and methods for treatment of colitis using methimazole and/or cyclic thione derivatives
AU2006247504B2 (en) Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with Toll-like receptors
JP7025781B2 (ja) ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法
US20210069192A1 (en) Use of neutrophil elastase inhibitors in liver disease
Yan et al. Beneficial effects of quinoline-3-carboxamide (ABR-215757) on atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice
CA2998509A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
Cairns et al. Bench to Bedside Tumor Necrosis Factor‐alpha: From Inflammation to Resuscitation
CA3012890A1 (en) Copanlisib biomarkers
EP3142655B1 (en) Compositions and methods of treating cardiac fibrosis with ifetroban
CA3012951A1 (en) Copanlisib biomarkers
US20210077582A1 (en) Compositions and methods for increasing the efficacy of anti-pd-1 antibody immunotherapy
ZA200604926B (en) Methods of treating acute inflammation in animals with p38 MAP kinase inhibitors
AU2017281980B2 (en) Wnt inhibitors for use in the treatment of fibrosis
US9717727B2 (en) Methods of treating and preventing leukemia and other cancers of the blood and bone
ES2383005T3 (es) Medicamentos para enfermedades glomerulares
CA2758829C (en) Method of treating demyelinating disease
El-Demerdash et al. Dapagliflozin targets the crosstalk between apoptosis, autophagy, and Hedgehog signaling pathways through AMPK activation in the adjuvant-induced arthritic rat model: AA El-Demerdash et al.
US20050209295A1 (en) Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
WO2005094819A1 (en) Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
CN117396505A (zh) 治疗炎症的方法
US20210322422A1 (en) Use of akt inhibitors in ophthalmology
Holson et al. Ercument Dirice1, Raymond Ng1, Rachael Martinez1, Jiang Hu1, Florence F. Wagner2
WO2011013302A1 (ja) 肝炎の治療剤もしくは予防剤
WO2015171985A1 (en) Treatment of igg-immune complex-mediated organ damage

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: OHIO UNIVERSITY

Free format text: FORMER OWNER WAS: INTERTHYR CORPORATION

MK14 Patent ceased section 143(a) (annual fees not paid) or expired